{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Matossian MD"],"funding":["NIBIB NIH HHS","NCI NIH HHS","National Institutes of Health","National Institute of General Medical Sciences","NIGMS NIH HHS","NIH HHS"],"pagination":["127-144"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8732292"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(1)"],"pubmed_abstract":["Metaplastic breast carcinoma (MBC) is a rare breast cancer subtype with rapid growth, high rates of metastasis, recurrence and drug resistance, and diverse molecular and histological heterogeneity. Patient-derived xenografts (PDXs) provide a translational tool and physiologically relevant system to evaluate tumor biology of rare subtypes. Here, we provide an in-depth comprehensive characterization of a new PDX model for MBC, TU-BcX-4IC. TU-BcX-4IC is a clinically aggressive tumor exhibiting rapid growth in vivo, spontaneous metastases, and elevated levels of cell-free DNA and circulating tumor cell DNA. Relative chemosensitivity of primary cells derived from TU-BcX-4IC was performed using the National Cancer Institute (NCI) oncology drug set, crystal violet staining, and cytotoxic live/dea"],"journal":["Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico"],"pubmed_title":["In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types."],"pmcid":["PMC8732292"],"funding_grant_id":["R01 CA174785","T34 GM136452","T32 EB027632","1R15CA176496-01A1","R01-CA125806-04","R15 CA176496","U54 GM104940","R01 CA125806","R01-CA174785-A1"],"pubmed_authors":["Zea AH","Brown H","Ochoa A","Elliott S","Baddoo M","Burks HE","Hebert KL","Sirenko O","Izadpanah R","Zabaleta J","Sabol RA","Martin EC","Wright MK","Windsor GO","Miele L","Moroz K","Matossian MD","King CT","Alzoubi MS","Chang T","Flemington E","Nguyen K","Bunnell BA","Riker AI","Burow ME","Sinha S","Wathieu H","Bursavich JB","Lau F","Cromwell EF","Savoie JJ","Ham AM","Collins-Burow BM"],"additional_accession":[]},"is_claimable":false,"name":"In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types.","description":"Metaplastic breast carcinoma (MBC) is a rare breast cancer subtype with rapid growth, high rates of metastasis, recurrence and drug resistance, and diverse molecular and histological heterogeneity. Patient-derived xenografts (PDXs) provide a translational tool and physiologically relevant system to evaluate tumor biology of rare subtypes. Here, we provide an in-depth comprehensive characterization of a new PDX model for MBC, TU-BcX-4IC. TU-BcX-4IC is a clinically aggressive tumor exhibiting rapid growth in vivo, spontaneous metastases, and elevated levels of cell-free DNA and circulating tumor cell DNA. Relative chemosensitivity of primary cells derived from TU-BcX-4IC was performed using the National Cancer Institute (NCI) oncology drug set, crystal violet staining, and cytotoxic live/dea","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2026-06-17T05:13:17.341Z","creation":"2022-02-11T15:22:54.749Z"},"accession":"S-EPMC8732292","cross_references":{"pubmed":["34370182"],"doi":["10.1007/s12094-021-02677-8"]}}